Pier 88 Investment Partners LLC Purchases Shares of 2,500 SPDR S&P Biotech ETF (NYSEARCA:XBI)

Pier 88 Investment Partners LLC acquired a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,500 shares of the exchange traded fund’s stock, valued at approximately $247,000.

Several other large investors have also modified their holdings of XBI. Hartline Investment Corp lifted its position in SPDR S&P Biotech ETF by 2.0% during the 3rd quarter. Hartline Investment Corp now owns 5,502 shares of the exchange traded fund’s stock worth $544,000 after acquiring an additional 106 shares during the last quarter. HBK Sorce Advisory LLC increased its stake in shares of SPDR S&P Biotech ETF by 2.6% in the first quarter. HBK Sorce Advisory LLC now owns 4,538 shares of the exchange traded fund’s stock worth $431,000 after purchasing an additional 113 shares during the period. Intellectus Partners LLC lifted its position in shares of SPDR S&P Biotech ETF by 1.0% during the 2nd quarter. Intellectus Partners LLC now owns 11,334 shares of the exchange traded fund’s stock worth $1,051,000 after purchasing an additional 113 shares during the last quarter. Pacific Center for Financial Services boosted its stake in SPDR S&P Biotech ETF by 2.8% during the 1st quarter. Pacific Center for Financial Services now owns 4,359 shares of the exchange traded fund’s stock valued at $414,000 after purchasing an additional 118 shares during the period. Finally, Kingsview Wealth Management LLC grew its holdings in SPDR S&P Biotech ETF by 3.8% in the 1st quarter. Kingsview Wealth Management LLC now owns 3,495 shares of the exchange traded fund’s stock valued at $332,000 after buying an additional 127 shares during the last quarter.

SPDR S&P Biotech ETF Trading Down 0.5 %

XBI opened at $100.01 on Thursday. SPDR S&P Biotech ETF has a 1-year low of $69.32 and a 1-year high of $105.47. The business has a 50 day moving average of $99.07 and a 200-day moving average of $95.98. The stock has a market capitalization of $7.62 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.